Commure vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
$200M funding 2025; $200M+ ARR (doubled 3 consecutive years); $6B valuation (merged Athelas); 130+ health systems; HCA partnership; acquired Augmedix $139M/Memora; healthcare RCM leader
About
Commure is a healthcare infrastructure company founded to modernize the operational and clinical technology layer of health systems, which have historically relied on fragmented, decades-old software systems for workflows ranging from patient communication to revenue cycle management. The company was co-founded by Tanay Tandon and emerged from General Catalyst's health system subsidiary model, which provides capital and technology directly to large hospital networks. Commure merged with Athelas — an AI-powered revenue cycle management company — in 2023, combining Athelas's proven RCM automation with Commure's broader health system workflow platform to create a more comprehensive enterprise offering.\n\nCommure's platform addresses operational challenges across the health system enterprise including clinical documentation, ambient AI scribing through its Commure Scribe product, revenue cycle automation, patient engagement, and care team communication. The acquisition of Augmedix in 2024 added a leading ambient clinical intelligence capability, enabling physicians to automatically generate clinical notes from patient encounters using AI. Commure serves 130+ health systems and counts HCA Healthcare — one of the largest for-profit hospital networks in the US — as a strategic partner, providing both market validation and scale distribution for its products.\n\nCommure has achieved $200 million+ in annual recurring revenue, doubling for three consecutive years — a growth trajectory that has pushed its valuation to approximately $6 billion. The company's model of embedding deeply within health system operations, rather than selling point solutions that compete at the application layer, creates high switching costs and durable revenue streams. As health systems face intensifying margin pressure and clinician burnout driven by administrative overhead, Commure's AI-driven automation of clinical and operational workflows addresses two of the most urgent priorities simultaneously.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.